MedTrace Logo

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2021-02-02

No results posted yet for this study

Summary

Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost

Conditions

Interventions

DRUG

latanoprost 0.005% ophthalmic solution

One drop in the evening in the affected eye(s) at 8:00pm

DRUG

Travoprost 004% sterile ophthalmic solution

One drop in the evening in the affected eye(s) at 8:00pm

DRUG

Bimatoprost .03% sterile ophthalmic solution

One drop in the evening in the affected eye(s) at 8:00pm

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2002-08-31
Completion
2002-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847483 on ClinicalTrials.gov